Translation of "Keloid scar" in German

If you have a history of excessive scarring and keloid scar formation, you should inform your doctor.

Patients with a history of keloid or hypertrophic scar formation should not undergo subcutaneous insertion, as difficulties in retrieving the implant are possible.

Sixmo is contraindicated in patients with a history of keloid or hypertrophic scar formation at the site where Sixmo would be implanted, as difficulties in retrieving the implant are possible (see section

They are general risks for surgeries under general anaesthesia (haemorrhage - hematoma, infection, pulmonary embolism, abnormal healing process, postoperative wound opening, keloid scar formation etc.), and also procedure-specific risks.

These are generally known risks related to surgeries under general anaesthesia.(haemorrhage - hematoma, infection, pulmonary embolism, abnormal healing process, keloid scar formation etc.)

There are generally known risks related to surgeries under general anaesthesia.(haemorrhage - hematoma, infection, pulmonary embolism, abnormal healing process, keloid scar formation etc.)

They are general risks for surgeries under general anaesthesia (haemorrhage - hematoma, infection, pulmonary embolism, abnormal healing process, postoperative wound opening, keloid scar formation etc.), and also procedure-specific risks. Â

They are general risks for surgeries under general anaesthesia (haemorrhage - hematoma, infection, pulmonary embolism, abnormal healing process, postoperative wound opening, keloid scar formation etc.), and also procedure-specific risks:

Keloid scars are some of the most unfortunate to develop due to their unsightliness.

In the case of open wounds, a reduced formation of keloids at the scar could be observed.

Unfortunately keloid scars (thickened scars) sometimes form.

She would trace her fingers along the numb keloid scars left by my top surgery.

Excessive scarring (keloid) is rare, but cannot be excluded.

In interaction with polyurethane components, skin regeneration can be optimized under semi- or occlusive conditions, which helps to normalize in particular, keloids and other scars.

The invention furthermore also relates to such a protein fraction for use in the aftertreatment of scars, keloids and inflammatory processes caused by the action of ionizing rays.

People who should not have treatment are those with an active skin disease or infection, women who are pregnant or breast feeding, insulin dependent diabetics, people with heart conditions and those who are prone to keloid scarring.

Keloid scars represent a bigger problem and they most frequently leave even more unpleasant scar tissue after repeated surgical intervention.

Mepiform is a thin and discreet connection, which is intended for the treatment of old and new hypertrophic and keloid scars.

The surface and appearance of hypertrophic and keloid scars can be considerably improved, softened and flattened by steroid injections shot into the scar.

Mepiform® is a thin and discreet dressing, designed for the management of both old and new hypertrophic and keloid scars.

In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring, naevi, diabetic retinopathy, proliferative vitreoretinopathy and disorders of the connective tissue (for example sarcoidosis).

In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitreoretinopathy and disorders of the connective tissue (for example sarcoidosis).

In the context of the present inventions, the term “fibrotic disorders” encompasses especially the following terms: hepatic fibrosis, hepatic cirrhosis, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, myelofibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (including after surgical interventions), naevi, diabetic retinopathy, proliferative vitreoretinopathy and disorders of the connective tissue (for example sarcoidosis).

In the context of the present invention, the term fibrotic disorders includes in particular the following disorders: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring, naevi, diabetic retinopathy, proliferative vitreoretinopathy and disorders of the connective tissue (for example sarcoidosis).

In the context of the present invention, the term “fibrotic disorders” encompasses particularly the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, cardiomyopathy, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy and proliferative vitroretinopathy.

In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy and proliferative vitroretinopathy.

In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, digital ulcerations, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitroretinopathy and disorders of the connective tissue (for example sarcoidosis).